Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifarotene 0.005% cream monotherapy for mild to moderate facial acne vulgaris in Egyptian patients
PACTR202510658002240Completed
- Sponsor
- Kafrelsheikh University
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trifarotene in acne vulgaris, sponsored by Kafrelsheikh University. Primary endpoint: Investigator Global Assessment. Started Dec 2024; status: completed.
02
Drugs
trifarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on PACTR202510658002240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202510658002240.